M.T.3’s LAVURCHIN® Receives Japanese Pharmaceutical Regulatory Approval as a Radiosensitizer for Dogs
TOKYO--(BUSINESS WIRE)--Malignant Tumor Treatment Technologies, Inc. (Headquarters: Tokyo; President and CEO: Toshiyasu Miyazaki; “M.T.3â€) announced…